# Gynecologic Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN
- Date: 2026-01-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Miriam Delacroix, MD
- Calendar frame: modern shifted

- Requested by: Lorna Achebe-Price, MD

## Reason for consultation

Postmenopausal bleeding for three weeks in a 60-year-old journalist, about eight years after her last period and with no hormone use. An office endometrial biopsy was taken today and a transvaginal ultrasound is booked this week. Please see her within two weeks to review both results with her and plan treatment if they show cancer or atypical hyperplasia. **S**

## History

Ms. Ifill, 60, is seen at the request of Dr. Achebe-Price two weeks after she first reported three weeks of postmenopausal bleeding. An office endometrial biopsy was taken at that visit, and a transvaginal ultrasound two days later. The biopsy shows endometrioid adenocarcinoma, and CT was done the following week. The bleeding is now occasional spotting; she has no pain, bowel or bladder change, or leg swelling. She takes no hormones. She works long days as a journalist and anchor and wants to keep working through treatment if possible, and to decide who is told. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; weight 74.2 kg; blood pressure 132/82, pulse 84 |
| Abdomen | Soft, non-tender; no mass or fluid |
| Pelvic | With a chaperone: small amount of blood at the cervical os; cervix normal; uterus mobile, slightly enlarged; no adnexal mass or parametrial thickening |
| Lymph nodes | No inguinal or supraclavicular nodes |

BP 132/82 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 74.2 kg; BMI 27.3 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Achebe-Price's intake note. Endometrial biopsy: endometrioid adenocarcinoma, FIGO grade 2; mismatch repair immunohistochemistry with loss of MLH1 and PMS2 and retained MSH2 and MSH6; p53 wild-type pattern. Transvaginal ultrasound: endometrium 16 mm, heterogeneous, with an irregular junction with the myometrium and internal flow; two small intramural fibroids; normal ovaries. CT of the chest, abdomen and pelvis: enlarged uterine cavity; a 1.5 cm right external iliac node and a 1.7 cm left para-aortic node below the renal veins; no liver, lung, bone or peritoneal lesion; no ascites. Today: CA-125 28 U/mL; hemoglobin 12.1 g/dL, platelets 274; creatinine 0.80 mg/dL; albumin 4.1 g/dL. Hemoglobin: 12.1 g/dL; White cell count: 6 10*3/uL; Absolute neutrophil count: 3.6 10*3/uL; Platelets: 274 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.8 mg/dL; eGFR (CKD-EPI 2021): 84 mL/min/1.73 m²; ALT: 19 U/L; AST: 21 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 4.1 g/dL; CA-125: 28 U/mL; PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Assessment

1. **Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient** (C54.1). The biopsy shows a low-grade endometrioid cancer that has lost MLH1 and PMS2, with a wild-type p53 pattern. The enlarged right pelvic and left para-aortic nodes on CT suggest stage IIIC disease; the final FIGO 2023 stage comes from surgery. The molecular class needs POLE sequencing on the surgical specimen as well: a POLE-mutated tumor carries an excellent outlook, a p53-abnormal one a poor outlook, and a mismatch repair deficient tumor responds strongly to immunotherapy. She is fit, and the disease on CT can be removed with a minimally invasive operation: total hysterectomy with removal of both tubes and ovaries, washings, sentinel lymph node mapping with indocyanine green, and removal of the enlarged pelvic and para-aortic nodes. If nodal disease is confirmed, I recommend dostarlimab with carboplatin and paclitaxel every three weeks for six cycles, then dostarlimab alone every six weeks for up to three years: for mismatch repair deficient advanced endometrial cancer this combination sharply lowers the risk of progression compared with chemotherapy alone. Radiation would be reserved for nodal disease left after treatment. The loss of MLH1 is the universal Lynch syndrome tumor screen; in most women of her age it comes from MLH1 promoter methylation in the tumor, which is acquired, not inherited. If methylation is found, germline testing is not needed; if it is not, she should have germline testing after counseling, and if a variant is found, her blood relatives should be offered cascade testing through a letter she can share. **S**

## Recommendations

1. Robotic-assisted total laparoscopic hysterectomy with removal of both tubes and ovaries, washings, sentinel lymph node mapping, and removal of the enlarged pelvic and para-aortic nodes, in two weeks.
2. MLH1 promoter methylation testing on the biopsy now; POLE sequencing and estrogen receptor on the surgical specimen; FIGO 2023 stage with the molecular class recorded.
3. Genetic counseling once the methylation result is back; germline testing only if MLH1 loss is not explained by methylation; cascade testing of blood relatives only if a germline variant is found.
4. If nodal disease is confirmed: dostarlimab 500 mg with carboplatin AUC 5 and paclitaxel 175 mg/m2 every 21 days for six cycles, then dostarlimab 1000 mg every six weeks for up to three years, after hepatitis B, hepatitis C and HIV screening.
5. Before each cycle: blood count, kidney and liver function, magnesium, glucose, TSH and free T4, and a morning cortisol; neuropathy and immune-related symptom checks at each visit; three-drug antiemetic prevention.
6. CA-125 is normal and should not be used to follow her; CT of the chest, abdomen and pelvis at the end of combination treatment.
7. Survivorship care after treatment: examination with a pelvic examination every three months for two years and CT every six months for three years for stage III disease, with no routine vaginal cytology; lymphedema checks; distress screening at each visit.

## Strengths and supports

- Lives alone in Washington, D.C.; has no children. Supports: a large extended family she is close to, many friends, and her church community **S**

## Communication

Discussed with Dr. Achebe-Price, who saw her the same day. The biopsy, ultrasound and CT were explained to Ms. Ifill, who chose surgery in two weeks; she decides who else receives this note. **S**

## Follow-up

Surgery in two weeks; review with the final pathology and the tumor board recommendation before the first cycle; Dr. Achebe-Price continues primary care and shares the monitoring. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026), National Comprehensive Cancer Network
- Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023), International Federation of Gynecology and Obstetrics
- Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023), New England Journal of Medicine
- Eskander RN, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer (NRG-GY018). N Engl J Med 2023;388(23):2159-2170 (PMID 36972022) (2023), New England Journal of Medicine
- JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (GlaxoSmithKline label)
- Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026), Society of Gynecologic Oncology
- ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014), American College of Obstetricians and Gynecologists
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026), Aether Forge
